{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"35.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"Sustained platelet response between the treatment groups was assessed by determining the number of participants who achieved a platelet count \\>=50 Gi/L during treatment with eltrombopag in \\>= 60% of assessments between Day 15 and Day 43 in the absence of rescue treatment were reported here.","groups":[{"description":"Par aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3:1 to 5 years) received eltrombopag matching placebo for 7 weeks.","id":"OG000","title":"Part 2 (Randomized Period) -Placebo"},{"description":"Par aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3:1 to 5 years) received eltrombopag for 7 weeks. The starting dose for Cohort 1 was 37.5 mg QD. For Cohort 2, starting dose was based on the body weight. Par with a body weight of \\<27 kg received 25 mg QD, and par with a body weight of \\>=27 kg received 50 mg QD. Par of East Asian ancestry with a body weight of \\<27 kg received 12.5 mg QD, and with a body weight of \\>=27 kg received 25 mg QD. For Cohort 3, the starting dose was 1.5 mg/kg QD and 0.8 mg/kg/day for par of East Asian ancestry. The maximum dose allowed was 2mg/kg and could not exceed 75 mg daily. For all par, individual dose titration was allowed based upon platelet response.","id":"OG001","title":"Part 2 (Randomized Period) - Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat (ITT) Population, only those participants enrolled in Part 2 of this study were analyzed.","reportingStatus":"POSTED","timeFrame":"Between Day 15 and Day 43 of Part 2","title":"Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}